[Physiological effects induced by dermorphin synthetic analogue--opilong].

The effects of repeated opilong injections in a dose of 50 microg/kg/day on subsequent learning of Wistar rats have been studied. The substance caused significant anxiolytic and analgesic effects, as the majority of animals could be learned (90% against 40% in control group) despite of painful stimulus preceding to education. Opilong in a small dose displaced a relation of excitatory-inhibit processes to significant prevalence of excitation although the substance was already absent in an organism for a long time.

[Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis].

Aim: to define the clinical value of changes in blood rheological properties and renal endothelial function in patients with hematuric and nephritic forms of chronic glomerulonephritis (CGN) and to ascertain whether the indices under study can be applied to assess the activity (progression) of nephritis and used as a prognostic criteria.

Subjects And Methods: Sixty-one patients, including 30 with hematuric nephritis (Group 1) and 31 with nephrotic nephritis (Group 2), were examined. A control group consisted of 12 healthy individuals.

[The fibrinolytic system in uric acid dysmetabolism].

The subjects of the study were 50 first-degree relatives of patients with uric acid (UA) dysmetabolism. The subjects were divided into three groups: 15 with hyperuricosuria and normal UA blood level (group 1), 17--with hyperuricosuria and hyperuricemia (group 2), and 18--with hyperuricemia and lowered UA clearance (group 3). All of them displayed inhibited urine fibrinolytic activity (UFA) and reduced urokinase activity.

[Urine fibrinolytic activity as an indicator of kidney damage in uric acid metabolic imbalance].

Aim: To determine functional fibrinolytic activity of the urine in patients with different forms of purine metabolism disorder.

Material And Methods: Uricemia, 24-h uricosuria, serum creatinine, GFR, maximal urinary specific gravity, urokinase activity in the urine, total fibrinolytic activity of the urine (TFAU), activity of plasminogen activator inhibitor (PAI) in blood were studied in 33 patients with genetically determined purine metabolism disorders.

Results: Patients with purine metabolism disorders vs controls had decreased TFAU and urokinase activity.

[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis].

Correlative interconnections between plasminogen activator (PA) activity (fibrin plate method) and level of urokinase antigen (Ag UAP) and tissue PA antigen (Ag TAP) in urine and blood (ELISA) were studied in 60 patients with chronic glomerulonephritis (CGN) and 38 patients with amyloidosis. The high degree of positive correlation between blood and urine initial PA activity and Ag UAP content was found. This suggests the possible leading role of UAP in formation of the basal fluctuations of fibrinolytic activity in blood and urine.

[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis].

To estimate the individual role of the plasminogen activators (PA) urokinase (u-PA) and tissue (t-PA) in the development of two renal diseases (the nephrotic forms of chronic glomerulonephritis (CGN) and amyloidosis, the baseline plasma and urine levels of u-PA and t-PA antigens, their functional activity (FPAA), and changes in these parameters were determined after protein loading test (0.7 g/kg). In healthy individuals and patients with amyloidosis, the baseline FPAA changes from 0 to the maximum were caused only by the alterations of u-PA levels, in those with CGN, they were induced by the changes in the content of u-PA and t-AP antigens.

[Activators and inhibitors of fibrinolysis in chronic glomerulonephritis and amyloidosis].

Functional activities of plasminogen activators (FPAA) and their inhibitors and plasminogen activators's (PA), antigen level were determined in 31 patients with chronic glomerulonephritis, 23 patients with amyloidosis and 15 healthy persons. High FPAA correlated with favourable prognosis of diseases, elevated PA antigen level and diminished alpha 1-antitrypsin, alpha 2-macroglobulin and antiactivator activities. There were decreased PA antigen level and increased inhibitor's activities in group with zero FPAA.

[The effect of piyavit on hemostatic processes and fibrinolysis in patients with ischemic heart disease].

The oral use of the drug Piavit (derived from freeze-dried medicinal leeches) in 50 patients with coronary heart disease for 7 days in a daily dose of 600 mg (20 patients) and 1200 mg (30 patients) caused a moderate dose-independent increase in enzymatic, fibrinolysis, non-enzymatic fibrinolysis and antithrombin III activity. In half the patients who had low fibrinolytic levels, the agent stimulated mainly the release of plasminogen activator on administration days of 2 and 7. In other 15 patients the activity of plasminogen activator remained unchanged, but non-enzymatic fibrinolysis enhanced.

[The venous occlusion test in assessing the fibrinolytic activity of the vascular endothelium in lupus nephritis patients].

A venous occlusion test was used to evaluate the reserves of the kidneys and that of vascular endothelium fibrinolytic activity (VEFA) in patients with lupus nephritis (LN). Prior to and following venous occlusion functional activity of plasminogen activators in plasma and urine (PAPU), plasma activity of antiactivator (PAAA), urokinase urine activity (UUA) were measured by fibrin plate lysis test in 24 patients with active LN, 6 SLE patients with intact kidneys, 10 healthy subjects. Venous occlusion test revealed normal reserve of plasma activator activity in mild LN and depletion of this reserve in LN patients with nephrotic syndrome and rapidly progressive LN.

[Tissue-type plasminogen activator in patients with lupus nephritis].

ELISA was used to measure tissue plasminogen activator antigen in blood plasma and urine of 42 patients with active lupus nephritis (16 with isolated urinary syndrome, 13 with nephrotic syndrome, 13 with rapidly progressive LN). Control groups consisted of 17 patients with inactive LN and 15 healthy subjects. Inhibition of fibrinolysis in vascular system correlating with the disease severity was found in patients with active LN.

[The functional activity of plasminogen activators in the blood plasma and urine of patients with lupus nephritis].

A fibrin plate technique was employed to study functional activity of plasminogen activators in plasma and urine (FAAP, FAAU), activity of antiactivator in plasma (AAAP), urokinase urine activity (UUA) in 35 lupus nephritis (LN) patients. The latter comprise 3 groups by the disease severity: 22 patients with active LN attended by urinary syndrome (group 1), 7 patients with LN associated with nephrotic syndrome (group 2), 6 patients with rapidly progressing LN (group 3). Control groups included 5 SLE patients with unaffected kidneys and 25 healthy subjects.

[Thrombolytic effect of urokinase upon various methods of administration into the body].

A preparation of urokinase, obtained from human kidney cell culture, was administered into rats at a single dose of 5,000-10,000 U/200 g of body mass in a variety of ways using intravenous, intraperitoneal and subcutaneous inoculations. After intraperitoneal and subcutaneous administrations an increase of fibrinolytic activity in blood was more long-term although less distinct; the phase of reactive hypercoagulation was only slightly detected within 24 hrs after these procedures. Thrombin-produced provocation of thrombosis led to a lesser ratio of death in these animals as compared with the animals group administered intravenously.

[The effect of a protein loading test on the fibrinolytic system in patients with chronic glomerulonephritis and amyloidosis].

Investigation of the reserves of the fibrinolytic system with the aid of protein stimulation was carried out in 10 patients with chronic glomerulonephritis and in 10 patients suffering from amyloidosis. All the patients manifested proteinuria exceeding 3.5 g/day and other symptoms of nephrotic syndrome of varying intensity.

[The fibrinolysis system in recurrent myocardial infarction].

Studies of blood fibrinolytic activity in 112 patients with repeated acute myocardial infarction or injury to the myocardium have revealed reduced fibrinolytic activity on non-heated fibrin plates, decreased plasmin activity and euglobulin+ fraction lysis, lowered levels of plasminogen activator, total nonenzymic fibrinolysis, antithrombin III, ++FFDP, and elevated soluble complexes of fibrin-monomer level. Complications of myocardial infarction presenting as thromboembolism; ciliary arrhythmia, chronic aneurysm with thrombosis are associated with still more marked disorders of the fibrinolysis system.

[Changes in the hemostasis and fibrinolysis system in rats with experimental renal hypertension].

The arterial renal hypertension (170-180 mm Hg compared to the norm 100-120 mm Hg) developed in 2 months after one side nephrectomy and partial occlusion of the other renal artery. The level of high molecular weight plasma proteins was raised which led to the increase in the peripheral vessel resistance and hypertension degree. Fibrinolysis was depressed in the blood and in the cortical zone of the kidney.

[The effect of thymoptin on enzymatic fibrinolysis].

Stimulation of fibrinolysis, decrease in content of fibrinogen and inhibitors were observed after intravenous, intramuscular or subcutaneous administrations of thymoptine preparation (complex of peptides, isolated from mammalian thymus) at doses of 0.1 microgram, 1.0 microgram/200 g of rat body mass.

[Effects of tissue-type plasminogen activator from a culture of calf kidney cells on hemostasis and fibrinolysis in experimental nephritis].

The plasminogen activator 960 IU/mg protein activity isolated from cultured fluid of the calf kidney cells was introduced to albino rats (180-200 g) with experimental Heynmann nephritis every day during 4 days. Nephritis caused activation of haemostasis and inhibition of fibrinolysis in the blood. There was increased excretion of the fibrin, fibrinogen degradation products in urine as a results of the local fibrin deposition in diseased kidneys.

[The role of fibrinolytic system in pneumonias complicated by exudative pleurisy in children].

Phasic alterations in fibrinolytic activity were found in blood plasma of children with pneumonia complicated by exudative pleurisy. Hypercoagulation and inhibition of fibrinolytic activity were observed at the beginning of the disease. Hypercoagulation and an increase in the fibrinolytic activity occurred during restoration.

[Participation of the kidney in changes in the fibrinolytic system during electroshock].

Fibrinolytic activity was studied in the renal vein of rats after electroshock. Electroshock increased distinctly the fibrinolytic activity in all parts of the venous system. The level of plasminogen activator was increased more in the renal vein and in the vena cava inferior, than in the jugular vein.

[Participation of the kidneys in the reaction of the anticoagulation system to thrombin administered into the blood stream].

Thrombin injection into white rats jugular vein in dose 20 units on 200 g of body mass results in more considerable release of plasminogen activator in blood of renal vein as compared with blood of cava inferior and jugular veins. In this case the fibrinolytic activity of kidney cortical part decreases, but in medullar part it does not alter. The decrease of antiplasmin content in blood of renal vein is due to alpha 2-macroglobulins, in blood of jugular and cava inferior veins--to alpha 1-antithrypsin.

[Fibrinolytic and thrombolytic properties of a plasminogen activator isolated from the culture broth of calf kidney cells].

Plasminogen activator isolated from cultural liquid of calf renal cells is an enzyme having a fibrinolytic action in vitro and in vivo, provoking a demonstrable thrombolytic effect, which depends on the drug dose, thrombus size and animal's body weight.